Patients who are treated with ICIs for bladder cancer are administered programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) antibody therapy at various stages of the disease. The gene discussed is PDCD1; the disease is urinary bladder carcinoma.